Focused Wealth Management Inc Sells 1,234 Shares of Johnson & Johnson (NYSE:JNJ)

Focused Wealth Management Inc reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,135 shares of the company’s stock after selling 1,234 shares during the period. Focused Wealth Management Inc’s holdings in Johnson & Johnson were worth $1,272,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Zions Bancorporation N.A. increased its position in Johnson & Johnson by 0.4% in the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock valued at $2,810,000 after buying an additional 73 shares in the last quarter. Cambridge Advisors Inc. increased its position in Johnson & Johnson by 0.3% in the 4th quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock valued at $2,895,000 after buying an additional 78 shares in the last quarter. Vishria Bird Financial Group LLC increased its position in Johnson & Johnson by 3.0% in the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock valued at $381,000 after buying an additional 80 shares in the last quarter. Burt Wealth Advisors increased its position in Johnson & Johnson by 0.6% in the 4th quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock valued at $1,665,000 after buying an additional 82 shares in the last quarter. Finally, Timber Creek Capital Management LLC increased its position in Johnson & Johnson by 8.7% in the 4th quarter. Timber Creek Capital Management LLC now owns 1,035 shares of the company’s stock valued at $133,000 after buying an additional 83 shares in the last quarter. 66.78% of the stock is owned by institutional investors and hedge funds.

In other Johnson & Johnson news, Director Marillyn A. Hewson bought 3,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $419,040. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.23% of the stock is owned by insiders.

A number of analysts recently commented on the company. Royal Bank of Canada boosted their target price on Johnson Service Group from GBX 180 ($2.35) to GBX 190 ($2.48) and gave the company an “outperform” rating in a research report on Tuesday, July 16th. Raymond James reaffirmed a “reduce” rating and issued a $48.00 target price (up from $45.00) on shares of Hancock Whitney in a research report on Wednesday, July 17th. Goldman Sachs Group set a $27.00 target price on Melco Resorts & Entertainment and gave the company a “buy” rating in a research report on Tuesday, May 28th. Wells Fargo & Co boosted their target price on Wingstop from $76.00 to $84.00 and gave the company an “outperform” rating in a research report on Monday, May 6th. Finally, Zacks Investment Research lowered Hallmark Financial Services from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $148.56.

JNJ stock traded down $1.00 during mid-day trading on Wednesday, reaching $131.08. 1,424,512 shares of the company traded hands, compared to its average volume of 6,897,555. The firm has a market cap of $348.90 billion, a PE ratio of 16.02, a price-to-earnings-growth ratio of 2.21 and a beta of 0.70. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The company has a 50 day simple moving average of $137.32.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 38.57% and a net margin of 20.08%. The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.10 EPS. On average, equities analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.90%. Johnson & Johnson’s payout ratio is presently 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is a Fiduciary?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.